TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.00200nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.00200nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.00900nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.00900nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.00900nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.236nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.236nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.356nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.356nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.356nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.5nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetCyclin-H/Cyclin-dependent kinase 7(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.623nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetCyclin-H/Cyclin-dependent kinase 7(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.623nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetCyclin-H/Cyclin-dependent kinase 7(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.623nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair